[Skip to Navigation]
October 1986

Encephalopathy in Chronic Renal Failure Responsive to Deferoxamine Therapy: Another Manifestation of Aluminum Neurotoxicity

Author Affiliations

From the Department of Medicine (Drs Sprague and Corwin) and Neurologic Sciences (Drs Wilson and Tanner), Rush-Presbyterian-St Luke's Medical Center, Rush Medical College, Chicago, and the Department of Medical Affairs, The Upjohn Co, Kalamazoo, Mich (Dr Mayor). Dr Sprague is now with the Section of Nephrology, Pritzker School of Medicine, University of Chicago.

Arch Intern Med. 1986;146(10):2063-2064. doi:10.1001/archinte.1986.00360220245039

• We describe a patient undergoing chronic hemodialysis who developed a neurologic syndrome consisting of seizures, progressive myoclonus, and mild dementia and who responded to chelation therapy with deferoxamine mesylate. Neither her serum nor bone aluminum concentrations indicated aluminum toxicity. However, the presence of a positive deferoxamine-infusion test was suggestive of an elevated body burden of aluminum. Treatment with deferoxamine resulted in marked clinical improvement in her neurologic status within two months. The utility of using the deferoxamineinfusion test rather than serum aluminum levels in evaluating aluminum toxicity in chronic renal failure is suggested.

(Arch Intern Med 1986;146:2063-2064)

Add or change institution